Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes

Obesity

Volumn 19, Issue 12, 2011, Pages 2310-2315

  Sathyanarayana, Padma ^a   Jogi, Medhavi ^a   Muthupillai, Raja ^b   Krishnamurthy, Ramkumar ^b   Samson, Susan L ^a   Bajaj, Mandeep ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b St Luke's Episcopal Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EXENDIN 4; FATTY ACID; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIET THERAPY; DRUG EFFICACY; FATTY LIVER; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADIPOSE TISSUE; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FATTY ACIDS, NONESTERIFIED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; METFORMIN; MIDDLE AGED; OBESITY; PEPTIDES; PPAR GAMMA; RECEPTORS, GLUCAGON; THIAZOLIDINEDIONES; TRIGLYCERIDES; VENOMS;

EID: 81855193976     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.152     Document Type: Article

References (29)

1. Kotronen A, Juurinen L, Hakkarainen A et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008;31:165-169.
2. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007;92: 3490-3497.
3. Bajaj M, Suraamornkul S, Piper P et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:200-206.
4. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
5. Bajaj M, Suraamornkul S, Pratipanawatr T et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003;52:1364-1370.
6. Ryysy L, Häkkinen AM, Goto T et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-758.
7. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802.
8. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-1017.
9. Promrat K, Lutchman G, Uwaifo GI et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-196.
10. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307.
11. Petersen KF, Dufour S, Befroy D et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005;54:603-608.
12. Zinman B, Hoogwerf BJ, Durán García S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-485.
13. Gutzwiller JP, Drewe J, Göke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541-R1544.
14. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999;22:1137-1143.
15. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286.
16. Samson SL, Gonzalez EV, Yechoor V et al. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther 2008;16:1805-1812.
17. Li L, Yang G, Li Q et al. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab 2008;10:921-930.
18. Ding X, Saxena NK, Lin S et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43:173-181.
19. Tiikkainen M, Häkkinen AM, Korsheninnikova E et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-2176.
20. Petersen KF, West AB, Reuben A, Rothman DL, Shulman GI. Noninvasive assessment of hepatic triglyceride content in humans with 13C nuclear magnetic resonance spectroscopy. Hepatology 1996;24:114-117.
21. De Vos P, Lefebvre AM, Miller SG et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 1996;98:1004-1009.
22. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953.
23. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
24. Xu A, Wang Y, Keshaw H et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
25. Abbasi F, Chang SA, Chu JW et al. Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol 2006;290:R139-R144.
26. Kim Chung le T, Hosaka T, Yoshida M et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 2009;390:613-618.
27. Redondo A, Trigo MV, Acitores A, Valverde I, Villanueva- Peñacarrillo ML. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 2003;204:43-50.
28. Gupta NA, Mells J, Dunham RM et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010;51:1584-1592.
29. Sanyal AJ, Chalasani N, Kowdley KV et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685.